3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
50
Prostatic Neoplasms
23
Lung Neoplasms
17
Breast Neoplasms
16
Squamous Cell Carcinoma of Head and Neck
13
Neoplasms
9
Stomach Neoplasms
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Neoplasm Metastasis
6
Head and Neck Neoplasms
6
Carcinoma, Transitional Cell
6
Urinary Bladder Neoplasms
5
Triple Negative Breast Neoplasms
5
Non-Muscle Invasive Bladder Neoplasms
5
Endometrial Neoplasms
5
Carcinoma, Squamous Cell
5
Prostatic Neoplasms, Castration-Resistant
4
Oropharyngeal Neoplasms
4
Small Cell Lung Carcinoma
3
Ovarian Neoplasms
3
Nasopharyngeal Carcinoma
3
HER2-positive Breast Cancer
3
Esophageal Squamous Cell Carcinoma
3
Carcinoma
3
Anatomic Stage I Breast Cancer AJCC v8
3
Adenocarcinoma
3
Vaccinia
2
Solid Tumors
2
Sarcoma
2
Salivary Gland Neoplasms
2
Interventions
fludarabine
2
durvalumab
2
Cyclophosphamide
2
ruxolitinib
1
repotrectinib
1
ponatinib
1
pembrolizumab
1
gilteritinib
1
fludarabine phosphate
1
cemiplimab
1
atezolizumab
1
Whole-Body Irradiation
1
Tacrolimus
1
Peripheral Blood Stem Cell Transplantation
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Nivolumab
1
Mycophenolic Acid
1
Mesna
1
Melphalan
1
Immunotherapy
1
Idarubicin
1
Granulocyte Colony-Stimulating Factor
1
Docetaxel
1
Cytarabine
1
Cisplatin
1
CPI-0610
1
Busulfan
1
Bone Marrow Transplantation
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
Docetaxel
×
90 days
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled